14-3-3σ and p63 play opposing roles in epidermal tumorigenesis

Carcinogenesis

Volumn 32, Issue 12, 2011, Pages 1782-1788

  Li, Qiutang ^a   Sambandam, Sumitha A T ^a   Lu, Helen J ^a   Thomson, Alexander ^a   Kim, Sung hye ^a   Lu, Huayi ^a,b   Xin, Ying ^a   Lu, Qingxian ^a  

^a University of Louisville School of Medicine   (United States)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

14 3 3SIGMA PROTEIN; 7,12 DIMETHYLBENZ[A]ANTHRACENE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN P63; RAS PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; EPIDERMIS CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; SKIN CARCINOMA; SKIN PAPILLOMA; SQUAMOUS CELL CARCINOMA;

14-3-3 PROTEINS; 9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BLOTTING, WESTERN; CARCINOGENS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE SILENCING; HOMEOSTASIS; KERATINOCYTES; MICE; MICE, MUTANT STRAINS; PHOSPHOPROTEINS; POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; TRANS-ACTIVATORS;

EID: 81855206510     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr207     Document Type: Article

References (35)

1. Benzinger,A. et al. (2005) Targeted proteomic analysis of 14-3-3 sigma, a p53 effector commonly silenced in cancer. Mol. Cell. Proteomics., 4, 785-795.
2. Bridges,D. et al. (2005) 14-3-3 proteins: a number of functions for a numbered protein. Sci. STKE., 296, re10.
3. Hermeking,H. et al. (2006) 14-3-3 proteins in cell cycle regulation. Semin. Cancer. Biol., 16, 183-192.
4. Herron,B.J. et al. (2005) A mutation in stratifin is responsible for the repeated epilation (Er) phenotype in mice. Nat. Genet., 37, 1210-1212.
5. Li,Q. et al. (2005) Identification of 14-3-3sigma mutation causing cutaneous abnormality in repeated-epilation mutant mouse. Proc. Natl Acad. Sci. USA, 102, 15977-15982.
6. Ferguson,A.T. et al. (2000) High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc. Natl Acad. Sci. USA, 97, 6049-6054.
7. Lodygin,D. et al. (2003) Analysis of 14-3-3 sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma. Oncogene, 22, 5519-5524.
8. Chan,T.A. et al. (1999) 14-3-3 Sigma is required to prevent mitotic catastrophe after DNA damage. Nature, 401, 616-620.
9. Hermeking,H. et al. (1997) 14-3-3 sigma is a p53-regulated inhibitor of G2/ M progression. Mol. Cell, 1, 3-11.
10. Mills,A.A. et al. (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature, 398, 708-713.
11. Yang,A. et al. (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature, 398, 714-718.
12. Su,X. et al. (2009) Rescue of key features of the p63-null epithelial phenotype by inactivation of Ink4a and Arf. EMBO J., 28, 1904-1915.
13. Truong,A.B. et al. (2006) p63 regulates proliferation and differentiation of developmentally mature keratinocytes. Genes Dev., 20, 3185-3197.
14. Westfall,M.D. et al. (2003) The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol. Cell. Biol., 23, 2264-2276.
15. Flores,E.R. et al. (2005) Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell, 7, 363-373.
16. Keyes,W.M. et al. (2006) p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc. Natl Acad. Sci. USA, 103, 8435-8440.
17. Xin,Y. et al. (2011) IKK1 control of epidermal differentiation is modulated by notch signaling. Am. J. Pathol., 178, 1568-1577.
18. Tiscornia,G. et al. (2006) Production and purification of lentiviral vectors. Nat. Protoc., 1, 241-245.
19. Lo Iacono,N. et al. (2008) Regulation of Dlx5 and Dlx6 gene expression by p63 is involved in EEC and SHFM congenital limb defects. Development, 135, 1377-1388.
20. King,K.E. et al. (2006) Unique domain functions of p63 isotypes that differentially regulate distinct aspects of epidermal homeostasis. Carcinogenesis, 27, 53-63.
21. Xin,Y. et al. (2010) 14-3-3sigma controls corneal epithelial cell proliferation and differentiation through the Notch signaling pathway. Biochem. Biophys. Res. Commun., 392, 593-598.
22. Reddy,A.L. et al. (1990) Increased sensitivity to two-stage skin carcinogenesis of mice heterozygous for the repeated epilation mutation (Er). Int. J. Cancer, 46, 928-930.
23. Dellambra,E. et al. (2000) Downregulation of 14-3-3sigma prevents clonal evolution and leads to immortalization of primary human keratinocytes. J. Cell Biol., 149, 1117-1130.
24. Hibi,K. et al. (2000) AIS is an oncogene amplified in squamous cell carcinoma. Proc. Natl Acad. Sci. USA, 97, 5462-5467.
25. Patturajan,M. et al. (2002) DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell, 1, 369-379.
26. Yamaguchi et al. (2000) Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma. Int. J. Cancer, 86, 684-689.
27. Parsa,R. et al. (1999) Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J. Invest. Dermatol., 113, 1099-1105.
28. Nylander,K. et al. (2000) Characterization of the expression pattern of p63 alpha and delta Np63 alpha in benign and malignant oral epithelial lesions. Int. J. Cancer, 87, 368-372.
29. Park,B.J. et al. (2000) Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res., 60, 3370-3374.
30. Crook,T. et al. (2000) High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene, 19, 3439-3444.
31. Karni-Schmidt,O. et al. (2011) Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am. J. Pathol., 178, 1350-1360.
32. Koga,F. et al. (2003) Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin. Cancer. Res., 9, 5501-5507.
33. Fomenkov,A. et al. (2004) RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle, 3, 1285-1295.
34. Lefkimmiatis,K. et al. (2009) p73 and p63 sustain cellular growth by transcriptional activation of cell cycle progression genes. Cancer Res., 69, 8563-8571.
35. Keyes,W.M. et al. (2011) DeltaNp63alpha is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. Cell Stem Cell, 8, 164-176.